FDA Designations to Development Programs and Quarterly Financial Results Schedules - Research Report on Valeant, Elan, Alkermes, Teva and Gilead

Editor Note: For more information about this release, please scroll to bottom

News provided by

Jul 23, 2013, 08:00 ET

NEW YORK, July 23, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Valeant Pharmaceuticals Intl. Inc. (NYSE: VRX), Elan Corporation, plc. (NYSE: ELN), Alkermes Plc. (NASDAQ; ALKS), Teva Pharmaceuticals Industries Ltd. (NYSE: TEVA) and Gilead Sciences, Inc. (NASDAQ: GILD). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Valeant Pharmaceuticals Intl. Inc. Research Report

On July 15, 2013, Valeant Pharmaceuticals Intl. Inc. (Valeant) announced that it will discuss its financial results for Q2 2013 via conference call and live Internet webcast on Wednesday, August 7, 2013 at 8:00 a.m. ET (5:00 p.m. PT). Valeant informed that the webcast can be accessed at its website, and an online archive of the webcast will be available following the end of the live call, also at the Company's website. The Full Research Report on Valeant Pharmaceuticals Intl. Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/9fdd_VRX]

Elan Corporation, plc. Research Report

On July 17, 2013, Elan Corporation, plc. (Elan) announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation to its development program of ELND005. The Company reported that ELND005 was submitted for the treatment of Neuropsychiatric Symptoms (NPS) in Alzheimer's disease (AD). As per Elan, its ongoing ELND005 clinical program includes the Phase 2 Study AG201 in patients with AD, who are experiencing at least moderate levels of agitation/aggression and the safety extension Study AG251. In other news dated July 10, 2013, Elan announced that it will release its Q2 2013 financial results on Wednesday, July 24, 2013 before the European and U.S. financial markets open, and hold a conference call at 8:30 a.m. ET/1:30 p.m. British Summer on the same day. The Full Research Report on Elan Corporation, plc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/e996_ELN]

Alkermes Plc. Research Report

On July 18, 2013, Alkermes plc. (Alkermes) announced that it will discuss its Q2 2013 financial results via conference call on Thursday, July 25, 2013 at 8:30 a.m. EDT. The Company informed that a replay of the conference call will be available from 10:30 a.m., July 25, 2013 through August 1, 2013. In other news, dated July 17, 2013, Alkermes announced the initiation of a phase 2 study of its novel oral atypical drug candidate - ALKS3831 - designed to be a broad spectrum treatment for schizophrenia. "We have designed ALKS 3831 as a broad spectrum schizophrenia agent addressing two specific patient subpopulations: patients who may benefit from attenuation of the significant weight gain often associated with olanzapine treatment; and patients with a dual diagnosis of substance abuse disorder, which often exacerbates their schizophrenia," said Elliot Ehrich, M.D., Chief Medical Officer of Alkermes. "This large, well-designed phase 2 study will provide data necessary for us to determine ALKS 3831's ability to attenuate weight gain commonly associated with olanzapine treatment." The Full Research Report on Alkermes Plc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/e2f3_ALKS]

Teva Pharmaceuticals Industries Ltd. Research Report

On July 16, 2013, Teva Pharmaceuticals Industries Ltd. (Teva) announced that it has scheduled to release its Q2 2013 financial results on Thursday, August 1, 2013 at 7:00 a.m. ET. A conference call, live webcast and Q&A session will follow on the same day at 8:00 a.m. ET. Teva also informed that a replay of the webcast will be available within 24 hours on the Company's website until August 8, 2013, 11:59 p.m ET. The Full Research Report on Teva Pharmaceuticals Industries Ltd. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/e3a3_TEVA]

Gilead Sciences, Inc. Research Report

On July 18, 2013, Gilead Sciences, Inc. (Gilead) announced that it will release its Q2 2013 financial results on Thursday, July 25, 2013 at 4:05 p.m. ET. A conference call to discuss the Company's financial results and general business updates will be hosted by Gilead's management and will be held at 4:30 p.m. on the same day. The conference call will be on the Company's website. The Full Research Report on Gilead Sciences, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/9898_GILD]

----

EDITOR NOTES:

This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
For any urgent concerns or inquiries, please contact us at [email protected].
Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

http://analystscorner.com

SOURCE Analysts' Corner